Q-omics provides the consensus-scored MIR550A2 profile across patient tissues and cancer cell-line models. MIR550A2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, MIR550A2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR550A2 RNA expression shows 8,543 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LAML, BRCA, and SARC as cancer lineages where MIR550A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR550A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR550A2 survival associations across molecular data types. MIR550A2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR550A2 RNA expression–survival associations across cancer types. High MIR550A2 expression shows unfavorable associations in LUSC, MESO and THCA, but favorable associations in LAML, ACC and SARC. The LAML Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LAML as the clearest survival context for MIR550A2 RNA expression.
This table summarizes MIR550A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR550A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR550A2 shows higher tumor expression in BRCA, KICH, KIRP and HNSC. The BRCA box plot shows higher MIR550A2 RNA expression in tumor versus normal tissue (log2 FC = +0.655, t-test p < 0.001).
This table shows molecular features associated with MIR550A2 in patient tissues and cancer cell lines. In patient samples, MIR550A2 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
